



March 16, 2023

XXXXX
XXXXX
XXXXX

Re: Request for Action on Medical Research Matter; Nonhuman Primate Model Crisis

Dear xxxx:

We, the undersigned companies, organizations and institutions are actively engaged in conducting and supporting essential medical research on virtually all diseases affecting the American population. Our companies and institutions represent the majority of drug and biomedical research and development work conducted in the United States, which is critical not only to preventing the spread of infectious diseases like COVID-19, but also for the development of new innovative treatments for cancer, diabetes, and a number of other diseases currently without effective treatment options.

We are currently experiencing a crisis in which 60% of the supply of non-human primates (NHPs) critical to this work are being denied permits by the U.S. Fish and Wildlife Service. This disruption will significantly slow the U.S. biopharmaceutical pipeline, stifle scientific advancement, impair research, halt industry-wide economic growth, and deprive patients of potentially life-saving treatments. The gravity of this situation cannot be understated. A sustainable solution to this critical issue is urgently needed for all stakeholders.

Non-human primates (NHP's) have been in high demand in recent years, due in part to the focus on biologic drug pipelines as well as the need to use these models in regulatory-required drug safety testing. Because of their close genetic, physiological, and behavioral similarity to humans, NHPs are often the only relevant animal models for critical translational research.

We understand the issue at hand is the alleged illegal inclusion of wild-caught animals with captive bred animals from Cambodia and agree with the long-term goal of suppliers needing to provide accurate descriptions of all legally imported animals. We are asking that our government work with us in finding both short-term and long-term solutions to this crisis such that the pipeline for lifesaving medications will continue without interruption

We are committed to convening conversations and sharing our knowledge, expertise, and insights with any and all public and private sector stakeholders in order to develop and facilitate the implementation of solutions. We look forward to partnering with the U.S. government to quickly secure the U.S. supply chain and find long-term solutions for nonhuman primate resource needs.

Sincerely,

Altasciences

American College of Neuropsychopharmacology

American Physiological Society (APS)

American Society for Pharmacology and Experimental Therapeutics

American Veterinary Medical Association (AVMA)

Americans for Medical Progress

Association for Research in Vision and Ophthalmology (ARVO)

Attralus

BioImpact Capital

Biotechnology Innovation Organization (BIO)

California Biomedical Research Association (CBRA)

Charles River Laboratories

Context Therapeutics

Emory National Primate Research Center

Federation of American Societies for Experimental Biology (FASEB)

Inotiv

Labcorp

Massachusetts Society for Medical Research (MSMR)

Missouri Biotechnology Association (MOBIO)

MPM Capital

Northern Biomedical Research

Oregon National Primate Research Center



Orna Therapeutics

ReNAgade Therapeutics

Texas Biomedical Research Institute

Texas Society for Biomedical Research (TSBR)

Tulane National Primate Research Center

Virscio, Inc.

Washington National Primate Research Center

Wisconsin National Primate Research Center